2ANK

orally active thrombin inhibitors in complex with thrombin and an exosite decapeptide

• Total interactions analyzed: 3
• Total true interactions: 2
• Strongest Interaction:
  • Chains: H-P
  • Int. Res.: 39
  • Norm. En. per Res.: -4.0914
• Hub Node: H(2)

All Interactions

Chains	Hydro. Bond Ener. (kJ/mol)	Elec. Ener. (kJ/mol)	VDW. Ener. (kJ/mol)	Tot. Stab. Ener. (kJ/mol)	#int. res.	# Short cont.	#Hydr. int.	#VDW pairs	#salt bridges	#Pot. fav. elec. int	#Pot. unfav. elec. int
H-L	-136.6407	-62.5413	333.903	134.721	103	29	3	15456	11	45	37
H-P	-24.3617	-6.05	-129.154	-159.5657	39	9	2	5865	0	16	4

Interface residues

• H-L: ALA132H, ALA1L, ALA22H, ARG126H, ARG137H, ARG14L, ARG15L, ARG206H, ARG4L, ARG50H, ASN159H, ASN204H, ASN205H, ASP116H, ASP125H, ASP14L, ASP186H, ASP1L, ASP21H, ASP49H, CYS122H, CYS1L, GLN131H, GLN209H, GLN239H, GLU127H, GLU13L, GLU14L, GLU164H, GLU186H, GLU1L, GLU23H, GLU8L, GLY133H, GLY136H, GLY14L, GLY184H, GLY1L, GLY25H, GLY2L, HIS119H, ILE118H, ILE14L, ILE162H, ILE24H, ILE47H, LEU123H, LEU129H, LEU12L, LEU130H, LEU14L, LEU160H, LEU3L, LEU46H, LEU6L, LYS10L, LYS135H, LYS14L, LYS185H, LYS186H, LYS202H, LYS235H, LYS9L, MET201H, MET210H, MET26H, PHE114H, PHE199H, PHE204H, PHE232H, PHE7L, PRO120H, PRO124H, PRO161H, PRO204H, PRO28H, PRO5L, SER115H, SER11L, SER129H, SER14L, SER1L, SER203H, SER20H, SER27H, SER48H, THR128H, THR14L, TRP207H, TRP29H, TYR117H, TYR134H, TYR14L, TYR184H, TYR208H, TYR225H, VAL121H, VAL138H, VAL157H, VAL158H, VAL163H, VAL167H, VAL200H
• H-P: ARG35H, ARG67H, ARG73H, ARG75H, ARG77H, ASN62H, ASP63H, GLN151H, GLN38H, GLN65P, GLU39H, GLU57P, GLU61H, GLU61P, GLU62P, GLU77H, GLU80H, GLY142H, ILE59P, ILE82H, LEU40H, LEU41H, LEU64H, LEU65H, LEU85H, LYS109H, LYS36H, LYS70H, MET32H, MET84H, PHE34H, PRO152H, PRO37H, PRO58P, SER72H, THR74H, TRP141H, TYR56P, TYR76H